Brind.

Theravance Biopharma operates within the biopharmaceutical sector and its stock performance was compared against the market index.

1 report, 1 independent Updated Aug 13
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.

What happened

Some supportReported by 1 outlet

Theravance Biopharma operates within the biopharmaceutical sector and its stock performance was compared against the market index.

Who's involved

What this event is mainly about

Keep exploring

The entities involved

Coverage

Newest first; wire copies grouped
  • ZacksTheravance Biopharma (TBPH) Reports Q2 Loss, Tops Revenue Estimates Theravance Biopharma (TBPH) came out with a quarterly loss of $0.08 per share versus the Zacks Consensus Estimate of a loss of $0.1